Keunchil Park

J. Ahn, M. Ahn, Keunchil Park, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy‐naive patients with extensive‐disease small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2009, Cancer.

Abstract B25: Serial monitoring of EGFR mutations in plasma and evaluation of EGFR mutation status in matched tissue and plasma from NSCLC patients treated with CO-1686.

P. Angenendt, H. Wakelee, L. Sequist, 2013 .

Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma.

Keunchil Park, Kihyun Kim, C. Jung, 2007, Clinical immunology.

Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy

J. Ahn, M. Ahn, Keunchil Park, 2010, Cancer.

Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma.

W. Lee, J. Ahn, Keunchil Park, 2007, Leukemia research.

Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY

J. Shih, Keunchil Park, C. Chiu, 2020, Cancer science.

Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice

Keunchil Park, Chun-Ming Tsai, S. Lim, 2022, Current oncology.

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report

Edward S. Kim, Keunchil Park, F. de Marinis, 2022, Frontiers in Oncology.

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

N. Girard, R. Govindan, Keunchil Park, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

J. Shih, Keunchil Park, S. Novello, 2019, The Lancet. Oncology.

Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma.

J. Ahn, M. Ahn, Keunchil Park, 2019, Lung cancer.

Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations

J. Shih, Keunchil Park, Yuh-Min Chen, 2021, International Journal of Clinical Oncology.

Analyses on prognostic factors following tri-modality therapy for stage IIIa non-small cell lung cancer.

Joon-Oh Park, Keunchil Park, Y. Shim, 2007, Lung cancer.

Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in Stage III non-small-cell lung cancer.

Keunchil Park, Y. Bang, E. Choi, 2002, International journal of radiation oncology, biology, physics.

Preoperative concurrent chemoradiotherapy for stage IIIA non-small cell lung cancer.

Keunchil Park, Y. Shim, K. Lee, 1999, Acta oncologica.

Integrative pathway enrichment analysis of multivariate omics data

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2020, Nature Communications.

Reduced transforming growth factor-β type II receptor (TGF-β RII) expression in adenocarcinoma of the lung

Keunchil Park, Y. Shim, Joungho Han, 1999 .

Expression of Transforming Growth Factor β Type II Receptor Reduces Tumorigenicity in Human Gastric Cancer Cells

Keunchil Park, Y. Bang, Jay H. Chang, 1997 .

rthotopic Lung C ancer M odel Induced by PC 14 PE 6

D. Nam, Z. Cui, J. Ahn, 2009 .

Mouse orthotopic lung cancer model induced by PC14PE6.

D. Nam, Z. Cui, J. Ahn, 2006, Cancer research and treatment : official journal of Korean Cancer Association.

Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma

Nayoung K. D. Kim, Jung-Il Lee, Y. Suh, 2020, Nature Communications.

A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients.

L. Sequist, G. MacBeath, Keunchil Park, 2014 .

Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2020, Communications Biology.

The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer.

J. Ahn, M. Ahn, Keunchil Park, 2010, Lung cancer.

Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery

M. Ahn, Keunchil Park, Y. Shim, 2016, Oncotarget.

Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study

M. Ahn, Keunchil Park, S. Thongprasert, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

Role of Chemotherapy in Stage II Nasopharyngeal Carcinoma Treated with Curative Radiotherapy

Keunchil Park, D. Heo, K. Keum, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

ERCC1 expression as a prognostic marker in N2(+) nonsmall‐cell lung cancer patients treated with platinum‐based neoadjuvant concurrent chemoradiotherapy

J. Ahn, M. Ahn, Keunchil Park, 2008, Cancer.

Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer.

Joon-Oh Park, Keunchil Park, Jeeyun Lee, 2005, Japanese journal of clinical oncology.

East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL)

J. Shih, Keunchil Park, E. Cho, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study

Joon-Oh Park, Keunchil Park, Jeeyun Lee, 2005, Cancer Chemotherapy and Pharmacology.

The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors

J. Ahn, M. Ahn, Keunchil Park, 2019, Clinical Cancer Research.

Prognosis of Non-Small Cell Lung Cancer with Synchronous Brain Metastases Treated with Gamma Knife Radiosurgery

Jung-Il Lee, D. Kong, D. Nam, 2006, Journal of Korean medical science.

A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non–Small‐Cell Lung Cancer

Keunchil Park, B. Han, T. Mok, 2018, Clinical lung cancer.

Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma

J. Ahn, M. Ahn, Keunchil Park, 2008, Investigational New Drugs.

Comprehensive molecular characterization of mitochondrial genomes in human cancers

J. Weinstein, P. Campbell, I. Martincorena, 2020, Nature Genetics.

Clinical outcomes of radiation therapy for clinical T4b oesophageal cancer with airway invasion

Yong Soo Choi, M. Ahn, Keunchil Park, 2018, Radiation Oncology.

Pathway and network analysis of more than 2500 whole cancer genomes

Nuno A. Fonseca, Icgc, Gary D Bader, 2020, Nature Communications.

Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity

J. Ahn, M. Ahn, Keunchil Park, 2020, Nature Communications.

The NHance® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients

G. V. van Dongen, Keunchil Park, P. Pauwels, 2021, Biomedicines.

Molecularly Targeted Therapy Using Bevacizumab for Non-Small Cell Lung Cancer: a Pilot Study for the New CT Response Criteria

Ho Yun Lee, M. Ahn, Keunchil Park, 2010, Korean journal of radiology.

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

Keunchil Park, N. Rizvi, J. Mazières, 2018, The Lancet. Oncology.

Clinical outcomes of atypical carcinoid tumors of the lung and thymus: 7-year experience of a rare malignancy at single institute

J. Ahn, M. Ahn, Keunchil Park, 2013, Medical Oncology.

Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study

Kyung Soo Lee, Myung-Ju Ahn, Ho Yun Lee, 2016, Cancer Imaging.

Is trimodality approach better then bimodality in stage IIIA, N2 positive non-small cell lung cancer?

Yong Soo Choi, Joon-Oh Park, J. Ahn, 2006, Lung cancer.

New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy.

Kyung Soo Lee, Chin A Yi, Myung Jin Chung, 2011, Lung cancer.

Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.

Keunchil Park, D. Gandara, J. Infante, 2013 .

Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging.

Kyung Soo Lee, Byung-Tae Kim, Joon Young Choi, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Patients With Nasopharyngeal Carcinoma Treated With Concurrent Chemoradiotherapy

J. Choi, M. Ahn, Keunchil Park, 2015, Clinical and experimental otorhinolaryngology.

Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor.

Ho Yun Lee, J. Ahn, M. Ahn, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

High Dose Involved Field Radiation Therapy as Salvage for Loco-Regional Recurrence of Non-Small Cell Lung Cancer

J. Ahn, M. Ahn, Keunchil Park, 2012, Yonsei medical journal.

Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.

E. Smit, Keunchil Park, P. Paik, 2022, Clinical lung cancer.

A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer

S. Choi, J. K. Lee, Joon-Oh Park, 2006, Journal of gastroenterology and hepatology.

ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

M. Ahn, Keunchil Park, T. Mok, 2012 .

Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer.

Joon-Oh Park, J. Ahn, M. Ahn, 2007, Lung cancer.

Clinical applicability of staging small cell lung cancer according to the seventh edition of the TNM staging system.

J. Choi, J. Ahn, M. Ahn, 2013, Lung cancer.

INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer

Keunchil Park, T. Mok, Yi-long Wu, 2011, BMC Cancer.

Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteria.

J. Ahn, M. Ahn, Keunchil Park, 2016, Lung cancer.

Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung Cancer: Results of an Exploratory Subgroup Analysis of a Phase III Trial

G. Scagliotti, Keunchil Park, Chih-Hsin Yang, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Erlotinib Monotherapy for Stage IIIB/IV Non-small Cell Lung Cancer: A Multicenter Trial by the Korean Cancer Study Group

J. Ahn, M. Ahn, Keunchil Park, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comparison of Survival in Advanced Non-Small Cell Lung Cancer Patients in the Pre- and Post-Gefitinib Eras

J. Ahn, M. Ahn, Keunchil Park, 2009, Oncology.

Lung cancer working group report.

T. Mitsudomi, Keunchil Park, T. Mok, 2010, Japanese journal of clinical oncology.

Phase II Clinical Trial of Genexol R ( Paclitaxel ) and Cisplatin for Patients with N on-Sm all Cell Lung Cancer

Keunchil Park, Y. Bang, Sang-We Kim, 2003 .

Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery

H. Seol, Jung-Il Lee, D. Kong, 2020, Journal of Korean Neurosurgical Society.

Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma

J. Ahn, M. Ahn, Keunchil Park, 2019, Journal of Immunotherapy for Cancer.

Involved-lesion radiation therapy after chemotherapy in limited-stage head-and-neck diffuse large B cell lymphoma.

Keunchil Park, W. Kim, H. Nam, 2010, International journal of radiation oncology, biology, physics.

Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma

M. Ahn, Keunchil Park, Y. Ko, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing

Jae Woo Choi, Sung Sook Lee, Keunchil Park, 2019, PloS one.

Gastrointestinal malignancies harbor actionable MET exon 14 deletions

Joon-Oh Park, H. Kim, S. Ou, 2015, Oncotarget.

Integrative genomic analysis of salivary duct carcinoma

Youngwook Kim, Keunchil Park, W. Park, 2020, Scientific Reports.

Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience

Yong Soo Choi, J. Ahn, M. Ahn, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).

M. Socinski, Keunchil Park, P. Dennis, 2021, Clinical lung cancer.

Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.

F. Cappuzzo, K. Syrigos, Michael Thomas, 2016, Lung cancer.

Randomized phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non–small cell lung cancer

Michael Thomas, Keunchil Park, T. Ciuleanu, 2016 .

Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer?

P. Jänne, C. Ki, J. Ahn, 2008, Clinical Cancer Research.

Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer ?

C. Ki, J. Ahn, M. Ahn, 2008 .

NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line

Su Jin Lee, S. J. Lee, Joon-Oh Park, 2015, Oncotarget.

NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line

Woo, Joon, Zachary, 2015, Oncotarget.

The Continuation of Erlotinib Treatment in Non-Small Cell Lung Cancer Patients Whose Brain Lesion Is the Only Site of Progression: Prospective Pilot Study

J. Ahn, M. Ahn, Keunchil Park, 2015 .

Efficacy and safety of dovitinib in pretreated patients with advanced squamous non‐small cell lung cancer with FGFR1 amplification: A single‐arm, phase 2 study

J. Ahn, M. Ahn, Keunchil Park, 2016, Cancer.

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.

Ying Cheng, Keunchil Park, Yi-long Wu, 2020, The Lancet. Respiratory medicine.

Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy.

J. Ahn, M. Ahn, Keunchil Park, 2020, Cancer.

First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials.

L. Sequist, Keunchil Park, Yi-long Wu, 2019, Lung cancer.

Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy.

J. Ahn, M. Ahn, Keunchil Park, 2011, International journal of radiation oncology, biology, physics.

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Johan Vansteenkiste, G. Scagliotti, Keunchil Park, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea

J. Ahn, M. Ahn, Keunchil Park, 2019, Cancer research and treatment : official journal of Korean Cancer Association.

The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.

Ho Yun Lee, J. Ahn, M. Ahn, 2016, Journal of thoracic disease.

Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients.

J. Ahn, M. Ahn, Keunchil Park, 2015, Pharmacogenomics.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection of Patients for Maintenance Therapy

Joon-Oh Park, J. Ahn, M. Ahn, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats

J. Ahn, M. Ahn, Keunchil Park, 2011, Cancer Chemotherapy and Pharmacology.

A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK.

F. Hirsch, J. Ahn, M. Ahn, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Successful treatment with crizotinib in mechanically ventilated patients with ALK positive non-small-cell lung cancer.

Su Jin Lee, S. J. Lee, J. Ahn, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study.

G. Scagliotti, Keunchil Park, S. Gans, 2009, European journal of cancer.

6521 POSTER Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC)

G. Scagliotti, Keunchil Park, U. Gatzemeier, 2007 .

Second-L ine C hem otherapy for A dvanced N on-sm all C ell L ung C ancer: Past, Present, and H ope for the F uture

Keunchil Park, 2003 .

Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma

Keunchil Park, Kihyun Kim, Byeong-Bae Park, 2008, Leukemia & lymphoma.

Nodal marginal zone B-cell lymphoma: analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma

Keunchil Park, Jeeyun Lee, Yeon-Hee Park, 2006, Annals of Hematology.

Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia

Keunchil Park, Yeon-Hee Park, Y. Ko, 2006, Annals of Hematology.

Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy.

Joon-Oh Park, Keunchil Park, Jeeyun Lee, 2005, European journal of cancer.

ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC).

G. Scagliotti, A. Shaw, Keunchil Park, 2015 .

Phase II Study of High-Dose Lovastatin in Patients with Advanced Gastric Adenocarcinoma

Keunchil Park, Sung-Soo Yoon, W. Kim, 2004, Investigational New Drugs.

Adjuvant therapy in stage IIIA-N2 non-small cell lung cancer after neoadjuvant concurrent chemoradiotherapy followed by surgery

Yong Soo Choi, M. Ahn, Keunchil Park, 2015, Journal of thoracic disease.

A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).

C. Schumann, M. Socinski, F. Hirsch, 2014 .

Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs. docetaxel in 2L/3L NSCLC (POPLAR)

Keunchil Park, J. Yi, J. Mazières, 2016, Pneumologie.

Korean Ethnicity as Compared with White Ethnicity Is an Independent Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer before and after the Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Era

J. Zell, A. Ziogas, J. Ahn, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors

J. Ahn, M. Ahn, Keunchil Park, 2021, Translational lung cancer research.

Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies.

Keunchil Park, T. Mok, Yi-long Wu, 2018, Lung cancer.

Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer.

J. Ahn, M. Ahn, Keunchil Park, 2020, Lung cancer.

Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?

J. Ahn, M. Ahn, Keunchil Park, 2020, Journal of thoracic disease.

The Relation between H istopathologic Findings on Surgical Specim en and O utcom es in Patients with N 2 Positive Stage IIIA N on-Sm all Cell Lung Cancer Receiving Preoperative Concurrent Radiochem otherapy and Surgery

Keunchil Park, Joungho Han, Jhingook Kim, 2004 .

Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2017, Oncotarget.

L-Ascorbic acid induces apoptosis in acute myeloid leukemia cells via hydrogen peroxide-mediated mechanisms.

Keunchil Park, W. Kim, B. Kimler, 2004, The international journal of biochemistry & cell biology.

L‐ascorbic acid represses constitutive activation of NF‐κB and COX‐2 expression in human acute myeloid leukemia, HL‐60

Keunchil Park, Y. Surh, B. Kimler, 2004, Journal of cellular biochemistry.

Interferon-α resistance can be reversed by inhibition of IFN-α-induced COX-2 expression potentially via STAT1 activation in A549 cells

Joon-Oh Park, J. Ahn, Keunchil Park, 2006 .

Curcumin inhibits interferon-α induced NF-κB and COX-2 in human A549 non-small cell lung cancer cells

Joon-Oh Park, J. Ahn, Keunchil Park, 2005 .

Regulatory (FoxP3+) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2020, Scientific Reports.

J. Ahn, M. Ahn, Keunchil Park, 2020, Oncoimmunology.

Therapeutic efficacy of Cancer vaccine Adjuvanted with Nanoemulsion loaded with TLR7/8 agonist in lung Cancer model.

J. Ahn, M. Ahn, Keunchil Park, 2021, Nanomedicine : nanotechnology, biology, and medicine.

Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea

M. Ahn, Keunchil Park, M. Kwon, 2020, BMC Cancer.

Abstract CT221: Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment for patients with advanced non-small cell lung cancer (NSCLC) with brain metastases: Results from CheckMate 227

K. Syrigos, Keunchil Park, H. Borghaei, 2020 .

Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.

L. Urban, K. O'Byrne, Keunchil Park, 2021 .

Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.

Keunchil Park, F. de Marinis, J. von Pawel, 2019, Lung cancer.

Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.

F. Hirsch, Keunchil Park, D. Gandara, 2021, Clinical lung cancer.

Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor

Yeon Jeong Kim, J. Ahn, M. Ahn, 2022, Oncology.

Afatinib as First‐line Treatment of Older Patients With EGFR Mutation‐Positive Non‐Small‐Cell Lung Cancer: Subgroup Analyses of the LUX‐Lung 3, LUX‐Lung 6, and LUX‐Lung 7 Trials

L. Sequist, K. O'Byrne, Keunchil Park, 2018, Clinical lung cancer.

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.

J. Ahn, M. Ahn, Keunchil Park, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prevalence of NUT carcinoma in head and neck: Analysis of 362 cases with literature review

M. Ahn, Keunchil Park, Hyung-Jin Kim, 2020, Head & neck.

Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.

Keunchil Park, N. Rizvi, J. Mazières, 2020, Lung cancer.

Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.

J. Ahn, M. Ahn, Keunchil Park, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study

Keunchil Park, D. Gandara, J. von Pawel, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Avelumab vs docetaxel in patients with platinum-treated advanced non-small-cell lung cancer: 2-year follow-up from the JAVELIN Lung 200 phase 3 trial.

Keunchil Park, F. de Marinis, M. Krzakowski, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non‐small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2021, European journal of immunology.

Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer

A. Drilon, Keunchil Park, S. Novello, 2021 .

Atezolizumab vs Docetaxel in Pretreated Patients with Non-Small Cell Lung Cancer: Final Results From the Randomized Phase II POPLAR and Phase III OAK Clinical Trials.

Keunchil Park, D. Gandara, J. Mazières, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase III study of selpercatinib vs chemotherapy +/- pembrolizumab in untreated RET positive non-small-cell lung cancer.

A. Drilon, Keunchil Park, S. Novello, 2020, Future oncology.

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.

L. Urban, K. O'Byrne, Keunchil Park, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Effect of Positive BoneMarrow EBV In situ Hybridization in Staging and Survival of Localized Extranodal Natural Killer / T-Cell Lymphoma , Nasal-Type

Keunchil Park, Jeeyun Lee, Yeon-Hee Park, 2007 .

Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck cancer

Y. Doki, Keunchil Park, Chih-Hung Hsu, 2022, Cancer medicine.

First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients

Joon-Oh Park, D. Nam, Keunchil Park, 2020, Therapeutic advances in medical oncology.

Pulmonary Complications After Hematopoietic Stem Cell Transplantation

Joon-Oh Park, Keunchil Park, Jeeyun Lee, 2006, Journal of Korean medical science.

Th ree Ca ses of Sy nchro no us So lid T um or and Mu ltiple Mye lo ma

Keunchil Park, Jeeyun Lee, Kihyun Kim, 2004 .

Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer.

J. Ahn, M. Ahn, Keunchil Park, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Short Report Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease

J. Ahn, M. Ahn, Keunchil Park, 2019 .

Nongastric marginal zone B‐cell lymphoma: Analysis of 247 cases

Keunchil Park, Jeeyun Lee, Yeon-Hee Park, 2007, American journal of hematology.

Prognostic factor analysis and proposed prognostic model for conventional treatment of high‐grade primary gastric lymphoma

Keunchil Park, Yeon-Hee Park, Y. Ko, 2006, European journal of haematology.

Primary gastric lymphoma of T-cell origin: clinicopathologic features and treatment outcome.

Keunchil Park, Yeon-Hee Park, Y. Ko, 2006, Leukemia research.

CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: Results of a multi center phase II study and quality of life evaluation

Keunchil Park, Jeeyun Lee, Yeon-Hee Park, 2006, Leukemia & lymphoma.

Primary pulmonary non-Hodgkin's lymphoma.

Joon-Oh Park, Keunchil Park, Jinny Park, 2004, Japanese journal of clinical oncology.

PL04a.02: OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses

Keunchil Park, D. Gandara, F. Ciardiello, 2017 .

Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract.

Keunchil Park, Byeong-Bae Park, W. Kim, 2007, Neoplasia.

Insulin-like growth factor binding protein-3, in association with IGF-1 receptor, can predict prognosis in squamous cell carcinoma of the head and neck.

M. Ahn, Keunchil Park, Yeon-Hee Park, 2011, Oral oncology.

Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer

M. Ahn, Keunchil Park, S. Lim, 2020, The Korean journal of internal medicine.

High incidence of mucosa-associated lymphoid tissue in primary thyroid lymphoma: A clinicopathologic study of 18 casesin the Korean population

Sung In Cho, Keunchil Park, Yeon-Hee Park, 2006, Leukemia & lymphoma.

Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission.

Keunchil Park, Jeeyun Lee, J. Cheong, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Clinical features and prognostic factors of patients with “peripheral T cell lymphoma, unspecified”

Keunchil Park, Y. Ko, Kihyun Kim, 2008, Annals of Hematology.

A Prospective Phase II Trial of Induction Chemotherapy with Docetaxel/Cisplatin for Masaoka Stage III/IV thymic Epithelial Tumors

Yong Soo Choi, Su Jin Lee, J. Ahn, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A prospective, phase II trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage III/IV thymic epithelial tumors.

Su Jin Lee, J. Ahn, M. Ahn, 2012 .

Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib.

J. Ahn, Keunchil Park, Y. Ko, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influential Factors for the Collection of Peripheral Blood Stem Cells and Engraftment in Acute Myeloid Leukemia Patients in First Complete Remission

Keunchil Park, Jeeyun Lee, Jinny Park, 2005, International journal of hematology.

Mechanistic Aspects of Green Tea as a Cancer Preventive: Effect of Components on Human Stomach Cancer Cell Lines

Keunchil Park, H. Fujiki, M. Suganuma, 1999, Japanese journal of cancer research : Gann.

Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR).

Keunchil Park, R. Perng, J. S. Lee, 2010 .

Genetic changes in the transforming growth factor f8 (TGF-fi) type II receptor gene in human gastric cancer cells: Correlation with sensitivity to growth inhibition by TGF-,

Kim, M. Sporn, A. Roberts, 2022 .

A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma

M. Ahn, Keunchil Park, Y. Shim, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Lipiodol nanoemulsions stabilized with polyglycerol-polycaprolactone block copolymers for theranostic applications

Keunchil Park, Y. Nam, Jee Seon Kim, 2017, Biomaterials Research.

A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumors (KCSG LU17-21).

J. Ahn, M. Ahn, Keunchil Park, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Role in HBV Pathogenesis

K. Flanders, Keunchil Park, Seong-Jin Kim, 1996 .

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.

Keunchil Park, F. de Marinis, M. Krzakowski, 2018, The Lancet. Oncology.

Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapy.

Su Jin Lee, M. Ahn, Keunchil Park, 2016, Japanese journal of clinical oncology.

Evaluating entrectinib as a treatment option for non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2020, Expert opinion on pharmacotherapy.

Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.

Joon-Oh Park, Keunchil Park, Jeeyun Lee, 2005, Oncology reports.

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

E. Smit, J. Heymach, Keunchil Park, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Dosimetric predictors for postoperative pulmonary complications in esophageal cancer following neoadjuvant chemoradiotherapy and surgery.

Yong Soo Choi, M. Ahn, Keunchil Park, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non–small-cell lung carcinoma

J. Ahn, M. Ahn, Keunchil Park, 2022, iScience.

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

K. O'Byrne, Keunchil Park, T. Mok, 2016, The Lancet. Oncology.

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations

Keunchil Park, E. Cho, Joo‐Hang Kim, 2021, BMC Cancer.

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors

Keunchil Park, B. Cho, Sang-We Kim, 2021, JTO clinical and research reports.

Afatinib for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: clinical implications of the LUX-Lung 7 study.

Keunchil Park, 2016, Annals of translational medicine.

LUX-Lung 7: is there enough data for a final conclusion? - Author's reply.

Keunchil Park, 2016, The Lancet. Oncology.

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases

Edward S. Kim, Jie Yang, Keunchil Park, 2022 .

Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).

Keunchil Park, E. Cho, Dong-Wan Kim, 2015 .

RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

J. Shih, Keunchil Park, S. Novello, 2019, Journal of Clinical Oncology.

Utility of positron emission-computed tomography for predicting pathological response in resectable oesophageal squamous cell carcinoma after neoadjuvant chemoradiation.

J. Choi, M. Ahn, Keunchil Park, 2020, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

CD4+CD56+CD68+hematopoietic tumor of probable plasmacytoid monocyte derivation with weak expression of cytoplasmic CD3.

Keunchil Park, Y. Ko, H. Ree, 2002, Journal of Korean medical science.

Prognostic value of 18F‐FDG PET/CT in patients with squamous cell carcinoma of the tonsil: Comparisons of volume‐based metabolic parameters

Kyung-Han Lee, J. Choi, Keunchil Park, 2013, Head & neck.

Clinical evaluation of incadronate in korean patients with malignancy-associated hypercalcemia: An open-label, multicenter study.

Sung-Bae Kim, Joon-Oh Park, Keunchil Park, 2007, Current therapeutic research, clinical and experimental.

ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis.

Su Jin Lee, J. Ahn, M. Ahn, 2012, Lung cancer.

Production of IL-12 from gene modified human dermal fibroblasts: A preclinical study for IL-12 cancer gene therapy

Keunchil Park, M. Lotze, S. Kim, 1997 .

ERRATUM: Role of Chemotherapy in Stage II Nasopharyngeal Carcinoma Treated with Curative Radiotherapy

Keunchil Park, D. Heo, K. Keum, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

Aggressive natural killer cell leukemia: clinical features and treatment outcome.

Keunchil Park, Y. Ko, Kihyun Kim, 2002, Haematologica.

Fate of patients with nasopharyngeal cancer who developed distant metastasis as first failure after definitive radiation therapy

M. Ahn, Keunchil Park, J. Noh, 2016, Head & neck.

First‐Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never‐Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non–Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study

M. Ahn, Keunchil Park, Chun-Ming Tsai, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Effect of Positive Bone Marrow EBV In situ Hybridization in Staging and Survival of Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal-Type

Keunchil Park, Jeeyun Lee, Yeon-Hee Park, 2007, Clinical Cancer Research.

Importance of open lung biopsy in the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies

Keunchil Park, K. Lee, Joungho Han, 2002, American journal of hematology.

Risk factors to predict outcome in critically ill cancer patients receiving chemotherapy in the intensive care unit

Keunchil Park, Hojoong Kim, O. Kwon, 2011, Supportive Care in Cancer.

Reply to Y.H. Kim and M. Mishima.

J. Ahn, Keunchil Park, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma.

J. Ahn, Keunchil Park, Sarah Park, 2007, Blood.

Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors

Su Jin Lee, Jung-Il Lee, D. Nam, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial.

M. Ahn, Keunchil Park, Chun-Ming Tsai, 2014, European journal of cancer.

Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma

J. Ahn, M. Ahn, Keunchil Park, 2022, Cancer medicine.

Fractionated stereotactic radiation therapy for locally recurrent nasopharynx cancer: Report of three cases

Keunchil Park, S. Huh, C. Baek, 1999, Head & neck.

Monensin‐mediated growth inhibition in acute myelogenous leukemia cells via cell cycle arrest and apoptosis

Keunchil Park, B. Kim, Young Y. Lee, 2002, International journal of cancer.

ASCEND‐8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low‐Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)‐Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

Jeffrey W. Scott, Keunchil Park, Dong-Wan Kim, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma

Joon-Oh Park, Keunchil Park, Jeeyun Lee, 2004, Cancer Chemotherapy and Pharmacology.

Profiles of infectious complications on the outcomes for the recipients of allogeneic hematopoietic stem cell transplantation

Keunchil Park, C. Jung, W. Kim, 2007 .

Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07)

Sin-Ho Jung, J. Ahn, M. Ahn, 2018, British Journal of Cancer.

Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity

Keunchil Park, Kihyun Kim, S. Kim, 2012, Investigational New Drugs.

What is stage II in high-grade primary gastric lymphoma? How to define the range of "localized disease".

Keunchil Park, Yeon-Hee Park, Y. Ko, 2007, Leukemia research.

Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma

Keunchil Park, Sarah Park, J. H. Lee, 2007, Leukemia & lymphoma.

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Carlos Barrios, Toyoaki Hida, Keunchil Park, 2017, The Lancet.

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Keunchil Park, J. Yi, J. Mazières, 2016, The Lancet.

Dynamics of circulating immune cells during chemoradiotherapy in patients with non-small cell lung cancer support earlier administration of anti-PD-1/PD-L1 therapy.

J. Ahn, M. Ahn, Keunchil Park, 2022, International journal of radiation oncology, biology, physics.

Influence of nano-carrier architecture on in vitro siRNA delivery performance and in vivo biodistribution: polyplexes vs micelleplexes.

Youngwook Kim, Z. Cui, Keunchil Park, 2011, ACS nano.

Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)

Sin-Ho Jung, Ho Yun Lee, J. Ahn, 2016, Oncotarget.

Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2015, Oncotarget.

Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy

J. Choi, M. Ahn, Keunchil Park, 2013, European Journal of Nuclear Medicine and Molecular Imaging.

A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01).

Sung-Bae Kim, M. Ahn, Keunchil Park, 2012, European journal of cancer.

Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation

J. Ahn, M. Ahn, Keunchil Park, 2012, Cancer Chemotherapy and Pharmacology.

Skeletal Muscle Metastasis and Elevated β-HCG Level Secondary to Tongue Cancer: a Case Report and Review of Literature

Keunchil Park, J. Lee, Se-Hoon Lee, 2015 .

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.

A. Drilon, Keunchil Park, Y. Ohe, 2020, The New England journal of medicine.

New Approaches to SCLC Therapy: From the Laboratory to the Clinic

M. Krasnow, Y. Pommier, C. Rudin, 2020 .

EGFR Mutation Testing Practices within the Asia Pacific Region

S. Toyooka, Y. Yatabe, Keunchil Park, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14‐01)

M. Ahn, Keunchil Park, J. Lee, 2017, Cancer.

Reappraisal of KIT mutation in adenoid cystic carcinomas of the salivary gland.

M. Ahn, Keunchil Park, Y. Ko, 2012, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma

M. Ahn, Keunchil Park, Y. Ko, 2014, Journal of Translational Medicine.

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

K. O'Byrne, Keunchil Park, F. de Marinis, 2012, The Lancet. Oncology.

Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).

J. Ahn, M. Ahn, Keunchil Park, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma

Jung-Il Lee, Y. Suh, J. Ahn, 2020, Nature Communications.

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.

C. Schumann, M. Socinski, R. Kurek, 2015, The Lancet. Oncology.

Analyses of non-coding somatic drivers in 2,658 cancer whole genomes

Jun Yu, Chen Hong, Ken Chen, 2020, Nature.

Comprehensive molecular characterization of mitochondrial genomes in human cancers

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2017, bioRxiv.

Patterns of somatic structural variation in human cancer genomes

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2020, Nature.

DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load

Jung Kyoon Choi, Manel Esteller, Myung-Ju Ahn, 2019, Nature Communications.

A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.

N. Girard, Keunchil Park, L. Paz-Ares, 2018 .

Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study

Keunchil Park, Y. Bang, Sang-We Kim, 2020, Targeted Oncology.

Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients

Hyun Cheol Chung, Sun Young Rha, Jae Won Yun, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer

Tae Yong Kim, Won Gu Kim, M. Ahn, 2018, Oncoimmunology.

Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors

J. Ahn, M. Ahn, Keunchil Park, 2017, Cancer Chemotherapy and Pharmacology.

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.

S. Ou, Keunchil Park, E. Cho, 2021 .

Reduces Tumorigenicity in Human Gastric Cancer Cells Type II Receptor β Expression of Transforming Growth Factor Updated

Keunchil Park, Y. Bang, Jay H. Chang, 2006 .

Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.

P. Park, Keunchil Park, Dong-Wan Kim, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2020, Nature Communications.

Pembrolizumab for the treatment of non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2016, Expert opinion on biological therapy.

Prevalence and detection of low-allele-fraction variants in clinical cancer samples

Jeong Eon Lee, P. Park, H. Kim, 2017, Nature Communications.

Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer

David A. Smith, G. Scagliotti, Keunchil Park, 2016, Investigational New Drugs.

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

G. Giaccone, M. Krasnow, C. Rudin, 2022 .

Clinicopathologic and Molecular Subtyping of EGFR Mutation-Response.

Keunchil Park, Jhingook Kim, H. Jung, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management

Keunchil Park, Yi-long Wu, P. Paik, 2022, Clinical lung cancer.

Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping

J. Ahn, M. Ahn, Keunchil Park, 2020, In Vivo.

Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.

J. Ahn, M. Ahn, Keunchil Park, 2019, Clinical lung cancer.

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model

J. Ahn, M. Ahn, Keunchil Park, 2018, PloS one.

Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01)

Ho Yun Lee, J. Ahn, M. Ahn, 2018, Journal of pathology and translational medicine.

Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?

G. Scagliotti, Keunchil Park, Yi-long Wu, 2017, Cancer treatment reviews.

An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2017, Expert review of molecular diagnostics.

EGFR TKI combination with immunotherapy in non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2017, Expert opinion on drug safety.

The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors

Joon-Oh Park, Keunchil Park, S. Park, 2016, Oncotarget.

Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation

Joon-Oh Park, J. Francis, M. Ahn, 2016, Oncotarget.

Metabolic Tumor Volume of [18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts Short-Term Outcome to Radiotherapy With or Without Chemotherapy in Pharyngeal Cancer

Jeon Yeob Jang, Sang Gyu Park, Joon Young Choi, 2009, Clinical Cancer Research.

Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors

D. Nam, J. Ahn, M. Ahn, 2019, BMC Ophthalmology.

Integrative pathway enrichment analysis of multivariate omics data

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2018, bioRxiv.

New approaches to small cell lung cancer therapy : from the laboratory to the clinic.

M. Krasnow, Y. Pommier, C. Rudin, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Imaging , Diagnosis , Prognosis Metabolic Tumor Volume of [ 18 F ]-Fluorodeoxyglucose Positron Emission Tomography / Computed Tomography Predicts Short-Term Outcome to Radiotherapy With or Without Chemotherapy in Pharyngeal Cancer

S. Hyun, J. Choi, M. Ahn, 2009 .

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer

Toyoaki Hida, Keunchil Park, D. Gandara, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II study of pembrolizumab for patients with previously treated advanced thymic epithelial tumor.

J. Ahn, M. Ahn, Keunchil Park, 2017 .

The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients

J. Ahn, M. Ahn, Keunchil Park, 2011, Journal of Cancer Research and Clinical Oncology.

Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer

Donggeun Yoo, J. Ahn, M. Ahn, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor Lysis Syndrome in a Solid Tumor: A Case Report of a Patient with Invasive Thymoma

J. H. Kim, J. Ahn, M. Ahn, 2013, Cancer research and treatment : official journal of Korean Cancer Association.

An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach.

Joon-Oh Park, Keunchil Park, Jeeyun Lee, 2005, International journal of radiation oncology, biology, physics.

Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs).

Keunchil Park, Dong-Wan Kim, Dae-Ho Lee, 2014 .

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

Yan Sun, Lucio Crino, Xiuyu Julie Cong, 2012, The Lancet. Oncology.

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

Hyae-Young Kim, J. Ahn, M. Ahn, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oxaliplatin and UFT Combination Chemotherapy in Patients With Metastatic Colorectal Cancer

Joon-Oh Park, W. Lee, Keunchil Park, 2002, American journal of clinical oncology.

Accelerating cancer omics and precision oncology in health care and research: a Lancet Oncology Commission.

Lincoln D. Stein, A. Biankin, Mélanie Courtot, 2023, The Lancet. Oncology.

Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).

Keunchil Park, Y. Bang, F. D. De Braud, 2020, European journal of cancer.

Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer

Joon-Oh Park, J. Ahn, Keunchil Park, 2006, Cancer Chemotherapy and Pharmacology.

First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.

M. Ahn, Keunchil Park, T. Mok, 2016, JAMA oncology.

20 – Clinical Presentation and Prognostic Factors in Lung Cancer

K. Nackaerts, Keunchil Park, K. Fong, 2018 .

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

K. Kelnar, Keunchil Park, A. Brenner, 2020, British Journal of Cancer.

EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations.

Edward S. Kim, Keunchil Park, J. Yang, 2021, Future oncology.

Clinical activity of ASP8273 in Asian patients with non‐small‐cell lung cancer with EGFR activating and T790M mutations

Keunchil Park, M. Fukuoka, K. Kiura, 2018, Cancer science.

High-throughput molecular genotyping for small biopsy samples in advanced non-small cell lung cancer patients.

Ho Yun Lee, J. Ahn, M. Ahn, 2013, Anticancer research.

Imaging genotyping of functional signaling pathways in lung squamous cell carcinoma using a radiomics approach

Sin-Ho Jung, Ho Yun Lee, Youngwook Kim, 2018, Scientific Reports.

A new KIT gene mutation in thymic cancer and a promising response to imatinib.

J. Ahn, M. Ahn, Keunchil Park, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight

Ho Yun Lee, M. Ahn, Keunchil Park, 2011, Cancer Chemotherapy and Pharmacology.

A review of the benefit–risk profile of gefitinib in Asian patients with advanced non‐small‐cell lung cancer

Keunchil Park, K. Goto, 2006, Current medical research and opinion.

Impact of diffusing lung capacity before and after neoadjuvant concurrent chemoradiation on postoperative pulmonary complications among patients with stage IIIA/N2 non-small-cell lung cancer

Ho Yun Lee, M. Ahn, Keunchil Park, 2020, Respiratory Research.

Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer

Michael Thomas, Keunchil Park, T. Ciuleanu, 2017, British Journal of Cancer.

Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA–Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis

Joon-Oh Park, Keunchil Park, S. Park, 2017, JCO precision oncology.

Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

Keunchil Park, M. Krzakowski, S. Ramalingam, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer

J. Ahn, M. Ahn, Keunchil Park, 2013, PloS one.

Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study.

Keunchil Park, Jeeyun Lee, Yeon-Hee Park, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery.

J. Ahn, M. Ahn, Keunchil Park, 2013, Lung cancer.

Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma

A. Drilon, Keunchil Park, S. Leyvraz, 2022, European journal of endocrinology.

Extrapulmonary small-cell carcinoma: a single-institution experience.

Joon-Oh Park, Keunchil Park, Jinny Park, 2004, Japanese journal of clinical oncology.

JuLI: accurate detection of DNA fusions in clinical sequencing for precision oncology.

Joon Seol Bae, Ki-Wook Lee, Hyun-Tae Shin, 2019, The Journal of molecular diagnostics : JMD.

Junction Location Identifier (JuLI)

M. Ahn, Keunchil Park, W. Park, 2019 .

JuLI: accurate detection of DNA fusions in clinical sequencing for precision oncology

Joon Seol Bae, Ki-Wook Lee, Hyun-Tae Shin, 2019, bioRxiv.

Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)

J. Ahn, M. Ahn, Keunchil Park, 2016, Oncotarget.

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.

I. Sohn, Sin-Ho Jung, J. Ahn, 2010, Lung cancer.

Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer

S. Hahn, Keunchil Park, Dong-Wan Kim, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Andreas Sashegyi, Michael Thomas, Federico Cappuzzo, 2014, The Lancet.

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.

J. Desai, R. Govindan, J. Krauss, 2020, The New England journal of medicine.

A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.

G. Scagliotti, Keunchil Park, F. de Marinis, 2010, Lung cancer.

Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphoma

Keunchil Park, Jeeyun Lee, Yeon-Hee Park, 2008, Medical oncology.

Pulmonary Strongyloidiasis with alveolar hemorrhage in a patient receiving chemotherapy

M. Ahn, Keunchil Park, Hui-Young Lee, 2009 .

Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center’s experiences

Joon-Oh Park, M. Ahn, Keunchil Park, 2017, Oncotarget.

AZD9291 overcomes T790 M-mediated resistance through degradation of EGFRL858R/T790M in non-small cell lung cancer cells

J. Ahn, M. Ahn, Keunchil Park, 2016, Investigational New Drugs.

Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.

Keunchil Park, S. Novello, M. Krzakowski, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vertical Magnetic Separation of Circulating Tumor Cells for Somatic Genomic-Alteration Analysis in Lung Cancer Patients

Je-Gun Joung, Hui-Sung Moon, Chang Eun Yoo, 2016, Scientific Reports.

Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.

Shibing Deng, J. Christensen, J. Ahn, 2013, Genomics.

A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib

J. Ahn, M. Ahn, Keunchil Park, 2015, Clinical Cancer Research.

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea

J. Ahn, M. Ahn, Keunchil Park, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors

J. Ahn, M. Ahn, Keunchil Park, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea.

M. Ahn, Keunchil Park, E. Cho, 2015, Lung cancer.

Vinorelbine, ifosfamide, and cisplatin combination as salvage chemotherapy in advanced non-small cell lung cancer.

Keunchil Park, O. Kwon, Y. Im, 2000, Japanese journal of clinical oncology.

Final Overall Survival, Other Efficacy and Safety Results from ASCEND-3: Phase II Study of Ceritinib in ALKi-Naïve Patients With ALK-Rearranged Non-Small-Cell Lung Cancer.

G. Scagliotti, A. Shaw, Keunchil Park, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2019, Investigational New Drugs.

Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.

J. Ahn, M. Ahn, Keunchil Park, 2019, Clinical lung cancer.

Presence of anaplastic lymphoma kinase translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case series

M. Ahn, Keunchil Park, Y. Ko, 2015, Head & neck.

Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer.

Ha Yeon Lee, J. Ahn, M. Ahn, 2013, Lung cancer.

Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer.

Shibing Deng, J. Ahn, M. Ahn, 2013, The Journal of molecular diagnostics : JMD.

Rapid detection of the epidermal growth factor receptor mutation in non-small-cell lung cancer for analysis of acquired resistance using molecular beacons.

T. Mitsudomi, Youngwook Kim, M. Ahn, 2010, The Journal of molecular diagnostics : JMD.

Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma

S. Paik, M. Ahn, Keunchil Park, 2015, Oncotarget.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non–Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21

J. Ahn, M. Ahn, Keunchil Park, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).

Keunchil Park, Yuh-Min Chen, R. Perng, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.

J. Ahn, M. Ahn, Keunchil Park, 2012, Histology and histopathology.

Molecular Medicine in Practice The EGFR T 790 M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor

Youngwook Kim, J. Ko, Z. Cui, 2012 .

Title : The EGFR T 790 M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor

Youngwook Kim, J. Ko, Z. Cui, 2011 .

Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC

J. Ahn, M. Ahn, Keunchil Park, 2018, Clinical pharmacology in drug development.

Real-world use of osimertinib in non–small cell lung cancer: ASTRIS study Korean subgroup analysis

Keunchil Park, Dong-Wan Kim, B. Cho, 2020, Current medical research and opinion.

Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer.

J. Ahn, M. Ahn, Keunchil Park, 2019, Lung cancer.

A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma

Keunchil Park, T. Mok, E. Tan, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases

J. Ahn, M. Ahn, Keunchil Park, 2016, Journal of pathology and translational medicine.

Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer.

Joon-Oh Park, J. Ahn, M. Ahn, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II Trial

M. Ahn, Keunchil Park, Dong-Wan Kim, 2020 .

Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib: A Phase I/II Trial

M. Ahn, Keunchil Park, Dong-Wan Kim, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.

J. Ahn, M. Ahn, Keunchil Park, 2013, Lung cancer.

Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience.

Keunchil Park, E. Cho, D. Heo, 2006, Lung cancer.

KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma.

J. Ahn, M. Ahn, Keunchil Park, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib.

G. Bepler, E. Smit, Keunchil Park, 2022, Clinical lung cancer.

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

A. Drilon, Keunchil Park, B. Cho, 2021, Clinical Cancer Research.

Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation.

Keunchil Park, G. Curigliano, G. Chang, 2021, Lung cancer.

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

R. Govindan, Keunchil Park, S. Peters, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial.

Keunchil Park, J. Vansteenkiste, J. Yang, 2021, Lung cancer.

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

Keunchil Park, T. Hsia, O. Molinier, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Olmutinib in T790M‐positive non–small cell lung cancer after failure of first‐line epidermal growth factor receptor‐tyrosine kinase inhibitor therapy: A global, phase 2 study

Keunchil Park, E. Felip, Dong-Wan Kim, 2021, Cancer.

Dynamic contrast-enhanced MRI for response evaluation of non-small cell lung cancer in therapy with epidermal growth factor receptor tyrosine kinase inhibitors: a pilot study.

M. Ahn, Keunchil Park, C. Yi, 2020, Annals of palliative medicine.

A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER

N. Girard, Keunchil Park, L. Paz-Ares, 2020, Frontiers in Oncology.

Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer

Keunchil Park, D. Planchard, L. Paz-Ares, 2020, Clinical Cancer Research.

The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2020, Translational lung cancer research.

Osimertinib improves overall survival in EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastases regardless of T790M mutational status.

J. Ahn, M. Ahn, Keunchil Park, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma.

J. Ahn, M. Ahn, Keunchil Park, 2020, European journal of cancer.

Genomic landscape of acquired resistance to third‐generation EGFR tyrosine kinase inhibitors in EGFR T790M‐mutant non–small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2020, Cancer.

Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice.

J. Ahn, M. Ahn, Keunchil Park, 2020, Japanese journal of clinical oncology.

Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease

Ho Yun Lee, J. Ahn, M. Ahn, 2019, International journal of cancer.

Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients.

M. Ahn, Keunchil Park, M. Chung, 2019, Clinical lung cancer.

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

L. Sequist, Keunchil Park, R. Doebele, 2019, The oncologist.

Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma

J. Ahn, M. Ahn, Keunchil Park, 2019, Journal of Cancer Research and Clinical Oncology.

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression

K. O'Byrne, Keunchil Park, T. Mok, 2019, Journal of Cancer Research and Clinical Oncology.

EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy

J. Ahn, M. Ahn, Keunchil Park, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

BIW-8962, an Anti GM2 Ganglioside Monoclonal Antibody, in Previously Treated Advanced/Recurrent Lung Cancer: a Phase I/II Study

Keunchil Park, B. Cho, Sang-We Kim, 2018, Journal of Cancer Biology and Therapeutics.

Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma

J. Ahn, M. Ahn, Keunchil Park, 2020, BMJ Open.

Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.

K. O'Byrne, Keunchil Park, T. Mok, 2019, Lung cancer.

A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test

J. Ahn, M. Ahn, Keunchil Park, 2015, Cancer Chemotherapy and Pharmacology.

Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?

Su Jin Lee, J. Ahn, M. Ahn, 2014, Cancer Chemotherapy and Pharmacology.

International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.

G. Scagliotti, Keunchil Park, Y. Ichinose, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects

Keunchil Park, Jeeyun Lee, I. Hwang, 2015, Supportive Care in Cancer.

Characteristics and outcomes of ALK+ non‐small cell lung cancer patients in Korea

M. Ahn, Keunchil Park, S. Lim, 2017, Asia-Pacific journal of clinical oncology.

Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy.

Ho Yun Lee, M. Ahn, Keunchil Park, 2015, Clinical lung cancer.

Efficacy and Safety of Erlotinib in 1242 East/South-East Asian Patients with Advanced Non-small Cell Lung Cancer

Keunchil Park, T. Mok, Yi-long Wu, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13

Ha Yeon Lee, Sin-Ho Jung, J. Ahn, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer

J. Shih, Keunchil Park, L. Paz-Ares, 2021, Clinical Cancer Research.

Phase 2 Study of the HSP‐90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer

H. Groen, L. Sequist, E. Smit, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)

C. Paweletz, P. Angenendt, H. Wakelee, 2016, Clinical Cancer Research.

Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy

J. Ahn, M. Ahn, Keunchil Park, 2010, Clinical Cancer Research.

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Database of 693 Cases.

Edward S. Kim, Keunchil Park, M. Schuler, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial.

Keunchil Park, E. Cho, Dong-Wan Kim, 2019, Lung cancer.

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting

Keunchil Park, J. Yang, I. Okamoto, 2019, Therapeutic advances in medical oncology.

Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR‐Mutated Advanced NSCLC

J. Ahn, M. Ahn, Keunchil Park, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?

Keunchil Park, Jong-Mu Sun, 2017, Current opinion in oncology.

Osimertinib for the treatment of non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2017, Expert opinion on pharmacotherapy.

Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs.

J. Ahn, M. Ahn, Keunchil Park, 2015, Lung cancer.

Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01)

J. Ahn, M. Ahn, Keunchil Park, 2012, Cancer.

Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild‐type nonsmall cell lung cancer treated with EGFR‐tyrosine kinase inhibitors

J. Ahn, M. Ahn, Keunchil Park, 2011, Cancer.

Prevalence and detection of low-allele-fraction variants in clinical cancer samples

Woo Yong Lee, Kyunghee Park, Kyoung-Mee Kim, 2017, Nature Communications.

The Outcomes of Hypertransfusion in Major ABO Incompatible Allogeneic Stem Cell Transplantation

Joon-Oh Park, Keunchil Park, S. Park, 2004, Journal of Korean medical science.

A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy.

J. Ahn, M. Ahn, Keunchil Park, 2013, Lung cancer.

Abstract 5287: Heterogeneity of mutation calling and annotation: a survey of cancer next-generation sequencing initiatives by the Global Alliance for Genomics and Health (GA4GH):

Subha Madhavan, Emmanuel Dias-Neto, Thomas J. Hudson, 2016 .

Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?

R. Kaiser, N. Pavlakis, Keunchil Park, 2019, Future oncology.

The Effectiveness of Maintenance Pharmacotherapies for Non-Small Cell Lung Cancer

M. Ahn, Keunchil Park, Jong-Mu Sun, 2012, Clinical Medicine Insights. Oncology.

Clinicopathological implications of EpCAM expression in adenocarcinoma of the lung.

Youngwook Kim, Z. Cui, J. Ahn, 2009, Anticancer research.

Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy

Youngwook Kim, J. Ahn, M. Ahn, 2011, Journal of Cancer Research and Clinical Oncology.

Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.

A. Rossi, C. Gridelli, Keunchil Park, 2014, The Lancet. Oncology.

Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience.

J. Ahn, M. Ahn, Keunchil Park, 2021, European journal of cancer.

MDSC subtypes and CD39 expression on CD8+ T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC

J. Ahn, M. Ahn, Keunchil Park, 2020, European journal of immunology.

BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2015, Investigational New Drugs.

Tumor-targeted delivery of paclitaxel using low density lipoprotein-mimetic solid lipid nanoparticles.

T. Park, Youngwook Kim, Keunchil Park, 2015, Molecular pharmaceutics.

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer

Keunchil Park, N. Reguart, S. Jabbour, 2021, JAMA oncology.

Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma

D. Choi, Joon-Oh Park, C. Ki, 2007, Cancer.

Increased Response Rates to Salvage Chemotherapy Administered after PD‐1/PD‐L1 Inhibitors in Patients with Non–Small Cell Lung Cancer

J. Ahn, M. Ahn, Keunchil Park, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Measuring response in solid tumors: comparison of RECIST and WHO response criteria.

Young Suk Park, Joon-Oh Park, Keunchil Park, 2003, Japanese journal of clinical oncology.

Nongastric marginal zone B-cell lymphoma: a prognostic model from a retrospective multicenter study.

Keunchil Park, Jeeyun Lee, Yeon-Hee Park, 2007, Cancer letters.

Treatment outcomes and clinicopathologic characteristics of triple‐negative breast cancer patients who received platinum‐containing chemotherapy

J. Ahn, Keunchil Park, Yeon-Hee Park, 2009, International journal of cancer.

A Multi-Center, Phase II Clinical Trial of Genexol(R) (Paclitaxel) and Cisplatin for Patients with Non-Small Cell Lung Cancer.

Keunchil Park, Y. Bang, Y. Im, 2003, Cancer research and treatment : official journal of Korean Cancer Association.

ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2021, Investigational New Drugs.

Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2‐Positive Non‐Small Cell Lung Cancer

Sin-Ho Jung, J. Ahn, M. Ahn, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.

J. Ahn, M. Ahn, Keunchil Park, 2014, Lung cancer.

Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer

Joon-Oh Park, Keunchil Park, Jeeyun Lee, 2005, Cancer Chemotherapy and Pharmacology.

Prospects and progress of atezolizumab in non-small cell lung cancer

Keunchil Park, J. Vansteenkiste, E. Wauters, 2017, Expert opinion on biological therapy.

Author Correction: Integrative pathway enrichment analysis of multivariate omics data

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2020, Nature Communications.

Characteristics and Outcome of ROS1‐Positive Non–Small Cell Lung Cancer Patients in Routine Clinical Practice

J. Ahn, M. Ahn, Keunchil Park, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.

A. Drilon, Keunchil Park, Melissa L. Johnson, 2018 .

Prognostic value of volumetric metabolic parameters measured by [18F]Fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer

J. Choi, M. Ahn, Keunchil Park, 2014, Cancer Imaging.

Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment

Su Jin Lee, J. Ahn, M. Ahn, 2009, Cancer.

Protein profiling in human sera for identification of potential lung cancer biomarkers using antibody microarray

Young-Pil Kim, Keunchil Park, Jhingook Kim, 2009, Proteomics.

Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis.

Keunchil Park, Kihyun Kim, Won Ki Kang, 2003, Biochemical and biophysical research communications.

The effect of pre-irradiation dose intense CHOP on anthracyline resistance in localized nasal NK/T-cell lymphoma.

Keunchil Park, Y. Ko, Kihyun Kim, 2006, Haematologica.

Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer

J. Ahn, M. Ahn, Keunchil Park, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment

J. Ahn, M. Ahn, Keunchil Park, 2010, Oncology.

CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer.

J. Desai, J. Krauss, Keunchil Park, 2020 .

Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment.

J. Ahn, M. Ahn, Keunchil Park, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer

G. Bepler, G. Scagliotti, Keunchil Park, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cerebral involvement of metastatic thymic carcinoma

Jung-Il Lee, D. Kong, D. Nam, 2005, Journal of Neuro-Oncology.

Clinical implications of esophagorespiratory fistulae in patients with esophageal squamous cell carcinoma (SCCA)

Keunchil Park, Yeon-Hee Park, Y. Im, 2010, Medical oncology.

Rapid detection of exon 2-deleted AIMP2 mutation as a potential biomarker for lung cancer by molecular beacons.

Youngwook Kim, Keunchil Park, Young-Su Jeong, 2013, Biosensors & bioelectronics.

Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Keunchil Park, Y. Ichinose, E. Cho, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization.

Kyung-Han Lee, J. Choi, Keunchil Park, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Tuberculosis in hematopoletk stem cell transplant recipients in Korea

Joon-Oh Park, Keunchil Park, Jeeyun Lee, 2004, International journal of hematology.

A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors

J. Ahn, M. Ahn, Keunchil Park, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Arsenic trioxide represses constitutive activation of NF‐κB and COX‐2 expression in human acute myeloid leukemia, HL‐60

Keunchil Park, B. Kimler, Kihyun Kim, 2005, Journal of cellular biochemistry.

Postremission therapy for acute myeloid leukemia in the first remission

J. Ahn, Keunchil Park, Jeeyun Lee, 2007, Leukemia & lymphoma.

Intestinal Lymphoma: Exploration of the Prognostic Factors and the Optimal Treatment

Joon-Oh Park, W. Lee, Keunchil Park, 2004, Leukemia & lymphoma.

The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations

J. Ahn, M. Ahn, Keunchil Park, 2012, Human Genetics.

The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations

J. Ahn, M. Ahn, Keunchil Park, 2011, Human Genetics.

Monensin inhibits the growth of renal cell carcinoma cells via cell cycle arrest or apoptosis.

Joon-Oh Park, Keunchil Park, Y. Im, 2003, International journal of oncology.

Orbital infiltration as the first site of relapse of primary testicular T-cell lymphoma.

Keunchil Park, Jeeyun Lee, Y. Ko, 2007, Cancer research and treatment : official journal of Korean Cancer Association.

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib

J. Ahn, M. Ahn, Keunchil Park, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Abstract CT079: ELUXA 1: Ph II study of BI1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)

P. Jänne, S. Ou, Keunchil Park, 2016 .

BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.

Keunchil Park, E. Cho, Dong-Wan Kim, 2016 .

NTRK gene amplification in patients with metastatic cancer

Joon-Oh Park, Keunchil Park, S. Park, 2017 .

A Single Nucleotide Polymorphism in the Phospholipase D1 Gene is Associated with Risk of Non-Small Cell Lung Cancer

J. Ahn, M. Ahn, Keunchil Park, 2012, International journal of biomedical science : IJBS.

Modest anti-cancer activity of a bile acid acylated heparin derivative in a PC14PE6 induced orthotopic lung cancer model.

Z. Cui, J. Ahn, M. Ahn, 2009, Cancer research and treatment : official journal of Korean Cancer Association.

Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease

Su Jin Lee, J. Ahn, M. Ahn, 2014, Cancer Chemotherapy and Pharmacology.

Sex differences in oncogenic mutational processes

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2019, Nature Communications.

A phase II trial of concurrent chemoradiotherapy with weekly docetaxel plus cisplatin treatment for unresectable locally advanced head and neck cancer

Sin-Ho Jung, M. Ahn, Keunchil Park, 2017 .

Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial.

Sin-Ho Jung, J. Ahn, M. Ahn, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy

J. Ahn, M. Ahn, Keunchil Park, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients

Joon-Oh Park, H. Kim, W. Lee, 2015, Oncotarget.

Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer

M. Ahn, Keunchil Park, W. Park, 2015, PLoS genetics.

Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: a prospective, multicenter trial.

J. Ahn, M. Ahn, Keunchil Park, 2009, Lung cancer.

Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02).

Sung-Bae Kim, Sin-Ho Jung, M. Ahn, 2016, Radiotherapy and Oncology.

Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer

Joon-Oh Park, Keunchil Park, S. Park, 2004, Clinical Cancer Research.

A case of petrous carotid artery pseudoaneurysm presenting with epistaxis after radiotherapy in a patient with nasopharyngeal cancer

Su Jin Lee, M. Ahn, Keunchil Park, 2010 .

Docetaxel Plus Cisplatin as Second-Line Therapy in Metastatic or Recurrent Advanced Gastric Cancer Progressing on 5-Fluorouracil-Based Regimen

Joon-Oh Park, Keunchil Park, S. Park, 2004, American journal of clinical oncology.

Trichostatin inhibits the growth of ACHN renal cell carcinoma cells via cell cycle arrest in association with p27, or apoptosis.

Joon-Oh Park, Keunchil Park, Y. Im, 2003, International journal of oncology.

Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray

J. Ahn, M. Ahn, Keunchil Park, 2010, Cancer.

A Prognostic Model to Predict Clinical Outcomes with First-Line Gemcitabine-Based Chemotherapy in Advanced Pancreatic Cancer

S. Choi, D. Choi, J. K. Lee, 2011, Oncology.

Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity

J. Ahn, M. Ahn, Keunchil Park, 2020, Nature Communications.

Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease.

M. Ahn, Keunchil Park, Y. Shim, 2016, Lung cancer.

Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2009, Cancer Chemotherapy and Pharmacology.

Preoperative Concurrent Radiochemotherapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer

Joon-Oh Park, Keunchil Park, Y. Shim, 2006, Journal of Korean medical science.

Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication

J. Ahn, M. Ahn, Keunchil Park, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC: Topic: Miscellaneous

Keunchil Park, R. Dziadziuszko, Dong-Wan Kim, 2017 .

A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC.

G. Bepler, E. Smit, Keunchil Park, 2016 .

Effects of transforming growth factor (TGF-) receptor on lung carcinogenesis

Keunchil Park, Haesung Kim, Yunseon Choi, 2002 .

Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy.

Keunchil Park, E. Cho, Dong-Wan Kim, 2018, Lung cancer.

The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma

J. Ahn, M. Ahn, Keunchil Park, 2009, Medical oncology.

Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.

J. Ahn, M. Ahn, Keunchil Park, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).

R. Govindan, Keunchil Park, E. Cho, 2019, Journal of Clinical Oncology.

High Dose Radiation Therapy Concurrent with Chemotherapy in Locally Advanced Nasopharynx Cancer.

Keunchil Park, D. Lim, S. Huh, 2003, Cancer research and treatment : official journal of Korean Cancer Association.

Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy.

J. Ahn, M. Ahn, Keunchil Park, 2018, Lung cancer.

Endobronchial Ultrasound versus Mediastinoscopy for Mediastinal Nodal Staging of Non–Small-Cell Lung Cancer

J. Choi, M. Ahn, Keunchil Park, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PD‐1 inhibitors for non‐small cell lung cancer patients with special issues: Real‐world evidence

J. Ahn, M. Ahn, Keunchil Park, 2020, Cancer medicine.

Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer.

J. Ahn, M. Ahn, Keunchil Park, 2018, Lung cancer.

Activation of Raf1 and the ERK pathway in response to l-ascorbic acid in acute myeloid leukemia cells.

Keunchil Park, B. Kimler, Kihyun Kim, 2005, Cellular signalling.

The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma

J. Ahn, M. Ahn, Keunchil Park, 2016, Oncotarget.

Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.

K. Syrigos, Keunchil Park, L. Paz-Ares, 2017, Lung cancer.

Biomarker driven phase II umbrella trial study of AZD1775, AZD2014, AZD2811 monotherapy in relapsed small cell lung cancer.

J. Ahn, M. Ahn, Keunchil Park, 2019, Journal of Clinical Oncology.

Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial.

T. Mitsudomi, M. Ahn, Keunchil Park, 2014 .

Low‐power and low‐drug‐dose photodynamic chemotherapy via the breakdown of tumor‐targeted micelles by reactive oxygen species

Keunchil Park, M. Yang, Jee Seon Kim, 2018, Journal of controlled release : official journal of the Controlled Release Society.

Prognostic role of insulin‐like growth factor receptor‐1 expression in small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Predictive factors for survival in stage IIIA N2 NSCLC patients treated with neoadjuvant CCRT followed by surgery

Ho Yun Lee, Keunchil Park, Y. Shim, 2014, Cancer Chemotherapy and Pharmacology.

MA 05.09 Pre-Existing Immunity Measured by Teff Gene Expression in Tumor Tissue is Associated with Atezolizumad Efficacy in NSCLC

P. Hegde, Keunchil Park, D. Gandara, 2017 .

P1.01-070 BIW-8962, an Anti-GM2 Ganglioside Monoclonal Antibody, in Advanced/Recurrent Lung Cancer: A Phase I/II Study

Keunchil Park, Sang-We Kim, Dae-Ho Lee, 2017 .

KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC.

Keunchil Park, N. Reguart, S. Jabbour, 2021 .

Comprehensive molecular characterization of mitochondrial genomes in human cancers

J. Weinstein, P. Campbell, I. Martincorena, 2020, Nature Genetics.

A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement.

J. Ahn, M. Ahn, Keunchil Park, 2016 .

Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study.

C. Ng, Keunchil Park, Yi-long Wu, 2012, Lung cancer.

Outcomes of Mediastinoscopy and Surgery with or without Neoadjuvant Therapy in Patients with Non-small Cell Lung Cancer Who are N2 Negative on Positron Emission Tomography and Computed Tomography

J. Choi, Keunchil Park, Y. Shim, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: Results from the randomized phase II study POPLAR.

Keunchil Park, J. Yi, J. Mazières, 2016 .

Efficacy and safety of dovitinib in pretreated advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase II study

J. Ahn, M. Ahn, Keunchil Park, 2016 .

Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors

D. Potvin, J. Christensen, Keunchil Park, 2022, Targeted Oncology.

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?

J. Ahn, M. Ahn, Keunchil Park, 2020, Biology.

Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).

Y. Doki, Keunchil Park, M. Ikeda, 2019, Journal of Clinical Oncology.

EGFR status and daily dose: Effect on tumor growth inhibition in cancer patients treated with dacomitinib (PF-00299804).

P. Jänne, Keunchil Park, N. Yamamoto, 2012 .

Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases.

J. Ahn, M. Ahn, Keunchil Park, 2011, Lung cancer.

Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001

A. Drilon, Keunchil Park, M. Lacouture, 2022 .

Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.

J. Ahn, M. Ahn, Keunchil Park, 2014, Lung cancer.

Nivolumab + chemotherapy vs chemotherapy in EGFR-mutated NSCLC after 1L or 2L EGFR-TKIs (CheckMate 722)

N. Girard, Keunchil Park, T. Mok, 2019, Annals of Oncology.

Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.

Keunchil Park, O. Arrieta, E. Swallow, 2016, Lung cancer.

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.

P. Postmus, Keunchil Park, R. Dziadziuszko, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

A. Drilon, Keunchil Park, B. Solomon, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis

J. Ahn, M. Ahn, Keunchil Park, 2016, Medical Oncology.

Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).

N. Girard, Keunchil Park, Dong-Wan Kim, 2020 .

Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001

A. Drilon, Keunchil Park, M. Lacouture, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC).

A. Drilon, Keunchil Park, B. Solomon, 2021 .

First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).

K. O'Byrne, Keunchil Park, T. Mok, 2016 .

P3.02b-044 Afatinib versus Gefitinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients Aged ≥75 Years: Subgroup Analysis of LUX-Lung 7: Topic: EGFR Clinical

K. O'Byrne, Keunchil Park, T. Mok, 2017 .

Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC for second-line treatment of stage IV non-small-cell lung cancer (NSCLC).

K. Syrigos, Keunchil Park, L. Paz-Ares, 2015 .

High concordance of actionable genomic alterations identified between circulating tumor DNA–based and tissue‐based next‐generation sequencing testing in advanced non–small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program

J. Ahn, M. Ahn, Keunchil Park, 2021, Cancer.

Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs

J. Ahn, M. Ahn, Keunchil Park, 2020, Immune network.

Whole-Section Landscape Analysis of Molecular Subtypes in Curatively Resected Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Significance.

M. Ahn, Keunchil Park, Y. Shim, 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision.

J. Ahn, M. Ahn, Keunchil Park, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Ethnic differences in non-small-cell lung cancer treatment: the Asian perspective

J. Ahn, M. Ahn, Keunchil Park, 2013 .

Stepwise evolution from a focal pure pulmonary ground-glass opacity nodule into an invasive lung adenocarcinoma: an observation for more than 10 years.

Kyung Soo Lee, Myung-Ju Ahn, Ho Yun Lee, 2010, Lung cancer.

Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non–Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis

Keunchil Park, Dong-Wan Kim, B. Cho, 2022, Cancer research and treatment.

Pretreatment Tumor 18F-FDG Uptake Improves Risk Stratification Beyond RECIST 1.1 in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: FDG Uptake and Risk Stratification

J. Choi, J. Ahn, M. Ahn, 2019, Clinical nuclear medicine.

Curcumin inhibits interferon-alpha induced NF-kappaB and COX-2 in human A549 non-small cell lung cancer cells.

Joon-Oh Park, J. Ahn, Keunchil Park, 2005, Biochemical and biophysical research communications.

A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.

Keunchil Park, O. Burghuber, Yuh-Min Chen, 2023, Future oncology.

Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial.

J. Ahn, M. Ahn, Keunchil Park, 2018, Lung cancer.

Phase II trial of combined durvalumab plus tremelimumab with proton therapy to boost the abscopal effect for recurrent or metastatic head and neck squamous cell carcinoma.

M. Ahn, Keunchil Park, Se-Hoon Lee, 2021 .

In Reply: DDR Pathway Alteration, Tumor Mutation Burden and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole-Exome and Targeted-Gene Sequencing.

Keunchil Park, Se-Hoon Lee, Sehhoon Park, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study.

Keunchil Park, D. Gandara, L. Fehrenbacher, 2017 .

A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma

S. Choi, D. Choi, J. K. Lee, 2007, Cancer Chemotherapy and Pharmacology.

Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer

M. Ahn, Keunchil Park, J. Lee, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Long-term Survival in Non–Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment

J. Ahn, M. Ahn, Keunchil Park, 2021, Cancer research and treatment.

Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.

J. Ahn, M. Ahn, Keunchil Park, 2010, Lung cancer.

Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator’s choice chemotherapy following progression on afatinib monotherapy.

J. Strausz, S. Ou, Keunchil Park, 2012 .

Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma.

Keunchil Park, Y. Shim, Jeeyun Lee, 2005, The Annals of thoracic surgery.

The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain

Keunchil Park, S. Park, H. Lee, 2014, The Korean journal of internal medicine.

Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

M. Ahn, Keunchil Park, W. Chang, 2018, The Korean journal of internal medicine.

The clinical efficacy of olaparib monotherapy or combination with ceralasertib (AZD6738) in relapsed small cell lung cancer.

J. Ahn, M. Ahn, Keunchil Park, 2021 .

Trends in Survival Rates of Non–Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020

J. Ahn, M. Ahn, Keunchil Park, 2023, JAMA network open.

Nanoparticulate carrier containing water-insoluble iodinated oil as a multifunctional contrast agent for computed tomography imaging.

Soo Won Seo, Jin Hoon Kim, Tae Gwan Park, 2007, Biomaterials.

Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies

Keunchil Park, Yi-long Wu, F. de Marinis, 2021, Frontiers in Oncology.

Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment

J. Ahn, M. Ahn, Keunchil Park, 2021, Translational lung cancer research.

Esophageal squamous cell carcinoma recurring as a solitary renal mass.

Joon-Oh Park, Keunchil Park, Y. Shim, 2004, Cancer research and treatment : official journal of Korean Cancer Association.

OA 05.07 Efficacy and Updated Safety of Ceritinib (450 Mg or 600 Mg) with Low-Fat Meal vs 750 Mg Fasted in ALK+ Metastatic NSCLC

P. Postmus, Keunchil Park, R. Dziadziuszko, 2017 .

Highly dense, optically inactive silica microbeads for the isolation and identification of circulating tumor cells.

Yeon Jeong Kim, Jong-Myeon Park, Keunchil Park, 2016, Biomaterials.

A Randomized Phase (PH) 2 Study with Exploratory Biomarker Analysis of Ficlatuzumab (F) A Humanized Hepatocyte Growth Factor (HGF) Inhibitory MAB in Combination with Gefitinib (G) Versus G in Asian Patients (PTS) with Lung Adenocarcinoma (LA)

Keunchil Park, T. Mok, E. Tan, 2012 .

The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis

Joon-Oh Park, H. Kim, J. Ahn, 2015, Oncotarget.

Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor.

Kyung-Han Lee, J. Ahn, M. Ahn, 2016, Lung cancer.

An open-label, multicenter, phase II single arm trial of osimertinib in non-small cell lung cancer patients with uncommon EGFR mutation (KCSG-LU15-09).

J. Ahn, M. Ahn, Keunchil Park, 2018 .

481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy

Keunchil Park, T. Mok, Y. Ohe, 2016 .

Do New pN Subclassifications Proposed by IASLC's Lung Cancer Staging Project Agree with ypN Categories after Trimodality Therapy for Initial N2 Disease?

J. Ahn, M. Ahn, Keunchil Park, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma

Keunchil Park, E. Cho, Y. Shim, 2008, Cancer Chemotherapy and Pharmacology.

A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers.

Joon-Oh Park, Keunchil Park, S. Park, 2003, Lung cancer.

Interferon-alpha resistance can be reversed by inhibition of IFN-alpha-induced COX-2 expression potentially via STAT1 activation in A549 cells.

Joon-Oh Park, J. Ahn, Keunchil Park, 2006, Oncology reports.

Nasal-type NK/T cell lymphoma: clinical features and treatment outcome

Keunchil Park, S. Lee, Y. Ko, 2005, British Journal of Cancer.

Hyperprogression after immunotherapy: Clinical implication and genomic alterations in advanced non-small cell lung cancer patients (NSCLC).

Ho Yun Lee, J. Ahn, M. Ahn, 2018 .

C3-06: ERCC1 expression as a predictive marker in stage IIIA, N2 positive non-small cell lung cancer patients treated with neoadjuvant concurrent chemoradiotherapy followed by surgery

J. Ahn, M. Ahn, Keunchil Park, 2007 .

Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer: Past, Present, and Hope for the Future.

Keunchil Park, 2003, Cancer research and treatment : official journal of Korean Cancer Association.

Longitudinal monitoring by next generation sequencing of plasma cell-free DNA in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with ALK tyrosine kinase inhibitors.

J. Ahn, M. Ahn, Keunchil Park, 2020 .

Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases?

Jung-Il Lee, D. Kong, D. Nam, 2010, Lung cancer.

CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFRm Non-Small-Cell Lung Cancer: A Brief Report.

Keunchil Park, G. Kar, D. Camidge, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer

J. Ahn, M. Ahn, Keunchil Park, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7)

K. O'Byrne, Keunchil Park, T. Mok, 2016 .

Safety of erlotinib in TRUST, a phase IV trial in patients with advanced non-small cell lung cancer (NSCLC): Initial results from the East/South East (E/SE) Asian subgroup

Keunchil Park, Yi-long Wu, H. Kuo, 2007 .

Pretreatment Clinical Mediastinal Nodal Bulk and Extent do not Influence Survival in N2-Positive Stage IIIA Non-small Cell Lung Cancer Patients Treated with Trimodality Therapy

J. Ahn, M. Ahn, Keunchil Park, 2014, Annals of Surgical Oncology.

Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea.

J. Ahn, M. Ahn, Keunchil Park, 2018, Lung cancer.

Prognostic Factors in Early-stage NSCLC: Analysis of the Placebo Group in the MAGRIT Study

Ying Cheng, Keunchil Park, R. Ramlau, 2019, AntiCancer Research.

Dry pleural dissemination in non-small cell lung cancer: prognostic and diagnostic implications.

Ho Yun Lee, M. Ahn, Keunchil Park, 2011, Radiology.

ICGC-ARGO precision medicine: an update on targeted therapy based on longitudinal analysis of tumour heterogeneity and evolution in colorectal cancer.

A. Biankin, Keunchil Park, A. Johns, 2023, The Lancet Oncology.

L1 cell adhesion molecule as a predictor for recurrence in pulmonary carcinoids and large‐cell neuroendocrine tumors

Youngwook Kim, Z. Cui, J. Ahn, 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial

M. Ahn, Keunchil Park, E. Cho, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification.

Keunchil Park, Y. Im, Y. Ko, 2002, European journal of cancer.

Bevacizumab plus atezolizumab following progression on atezolizumab monotherapy in pretreated non-small cell lung cancer patients: An open-label, two-stage, phase II trial.

J. Ahn, M. Ahn, Keunchil Park, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prevalence and detection of low-allele-fraction variants in clinical cancer samples

P. Park, H. Kim, W. Lee, 2017, Nature Communications.

A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma

M. Ahn, Keunchil Park, Y. Shim, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).

T. Mitsudomi, M. Ahn, Keunchil Park, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of Afatinib as third-line treatment for patients in Korea with stage IIIB/IV non-small cell lung cancer harboring wild-type EGFR.

J. Ahn, M. Ahn, Keunchil Park, 2014, The oncologist.

Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR.

J. Ahn, M. Ahn, Keunchil Park, 2015, The Oncologist.

Analyses of non-coding somatic drivers in 2,658 cancer whole genomes

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2020, Nature.

Dual-Energy CT in Patients Treated with Anti-Angiogenic Agents for Non-Small Cell Lung Cancer: New Method of Monitoring Tumor Response?

J. Seo, Ho Yun Lee, M. Ahn, 2012, Korean journal of radiology.

Aggressive natural killer cell leukemia: clinical features and treatment outcome.

Keunchil Park, Y. Ko, Kihyun Kim, 2002, Haematologica.

Phase II Study of Gemcitabine Combined with Uracil-Tegafur in Metastatic Pancreatic Cancer

S. Choi, Joon-Oh Park, Keunchil Park, 2004, Oncology.

Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment.

Keunchil Park, M. Aapro, J. von Pawel, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation

J. Ahn, M. Ahn, Keunchil Park, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial

J. Ahn, M. Ahn, Keunchil Park, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

FDG PET / CT and Mediastinal Nodal Metastasis Detection in Stage T 1 Non-Small Cell Lung Cancer : Prognostic Implications

Keunchil Park, Y. Shim, K. Lee, 2008 .

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

R. Greil, O. Popovych, C. Gridelli, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

9021 Preliminary results of MAGE-A3 expression and baseline demographic data from MAGRIT, a large phase III trial of MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic) in adjuvant NSCLC

D. Atanackovic, J. Strausz, Keunchil Park, 2009 .

190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI).

P. Jänne, S. Ou, Keunchil Park, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study.

K. O'Byrne, Keunchil Park, F. de Marinis, 2012, Lung cancer.

Haemodynamic analysis of adult patients with moyamoya disease: CT perfusion and DSA gradings

J. Ahn, Keunchil Park, Soohyun Hwang, 2020, Stroke and vascular neurology.

Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

M. Ahn, Keunchil Park, H. Jung, 2023, Cancer research and treatment.

Multimodal Treatments and Outcomes for Anaplastic Thyroid Cancer Before and After Tyrosine Kinase Inhibitor Therapy: A Real-World Experience.

M. Ahn, Keunchil Park, W. Park, 2021, European journal of endocrinology.

Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22

Keunchil Park, Y. Min, K. Lee, 2021, Translational Lung Cancer Research.

Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.

Sin-Ho Jung, M. Ahn, Keunchil Park, 2016, European journal of cancer.

Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer

Tae Yong Kim, Won Gu Kim, M. Ahn, 2018, Oncoimmunology.

Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?

G. Scagliotti, Keunchil Park, Yi-long Wu, 2017, Cancer treatment reviews.

Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer

J. Ahn, M. Ahn, Keunchil Park, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

C. Schumann, M. Socinski, R. Kurek, 2015, The Lancet. Oncology.

Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.

K. O'Byrne, Keunchil Park, T. Mok, 2019, Lung cancer.

Keunchil Park, Yuh-Min Chen, R. Perng, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes of Gamma Knife Radiosurgery in Combination with Crizotinib for Patients with Brain Metastasis from Non-Small Cell Lung Cancer.

H. Seol, Jung-Il Lee, D. Kong, 2016, World neurosurgery.

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting

Keunchil Park, J. Yang, I. Okamoto, 2019, Therapeutic advances in medical oncology.

The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer.

J. Ahn, M. Ahn, Keunchil Park, 2013, Lung cancer.

International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.

G. Scagliotti, Keunchil Park, Y. Ichinose, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Keunchil Park, Y. Ichinose, E. Cho, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer.

D. Na, J. Ahn, Keunchil Park, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.

J. Ahn, M. Ahn, Keunchil Park, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy

J. Ahn, M. Ahn, Keunchil Park, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study.

Keunchil Park, D. Gandara, J. von Pawel, 2019, European journal of cancer.

A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumors (KCSG LU17-21).

J. Ahn, M. Ahn, Keunchil Park, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study.

R. Govindan, Keunchil Park, S. Peters, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

G. Scagliotti, Keunchil Park, F. de Marinis, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement

J. Ahn, M. Ahn, Keunchil Park, 2023, Cancer research and treatment.

Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.

Keunchil Park, S. Novello, M. Krzakowski, 2014, Journal of Clinical Oncology.

Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study.

K. O'Byrne, Keunchil Park, R. Ramlau, 2012, Lung cancer.

9158 A phase III study of erlotinib as maintenance therapy in NSCLC to delay progression following first-line chemotherapy (SATURN)

G. Giaccone, F. Cappuzzo, Keunchil Park, 2009 .